Cliff Reid, CEO, Complete GenomicsBio and Contact Info
Listen (3:55) What do you make of recent crackdown on genetic testing in China?
Listen (5:19) Self pay model better for health care
Listen (2:08) What is the right level of regulation?
Listen (5:22) A two-tiered approach to delivering genomic information
Listen (2:00) How has your focus changed since the buyout?
Listen (3:48) FDA regulation not the only way to raise quality of genomic testing
Listen (2:11) What's your reaction to Illumina announcement of $1,000 genome?
Listen (4:13) What is the cost for genome interpretation today?
In a recent blog, 5 Myths of Genomic Medicine, we quoted Cliff Reid, CEO of Complete Genomics, as saying that the mainstream adoption of genomic medicine might well happen first in a country outside the U.S. and very likely in China where there is more appetite for risk.
Well, a month ago or so, many of us were surprised to read that China is cracking down on genetic testing. So for our first show in a new series, Regulation and Genomic Medicine, we invited Cliff to come back on the program and tell us what he knows about the recent regulatory actions in China and how Complete's parent company, BGI, is responding.
What is the right level of regulation back here in the U.S.? And what is Cliff's reaction to the recent letter sent by the FDA to 23andMe stopping the sale of health related genomic information?
In his answers, Cliff hints at a possible two-tiered system for delivering genomic data: one avenue through the clinics that is regulated by the FDA, the other directly to consumers in a 'interpret the data on your own' kind of way.
What's are his thoughts on Illumina's claim to the $1,000 genome, and how costly is human genome interpretation today? Cliff is forthright, provocative, and prescient.
Podcast brought to you by: Myraqa Clinical Research: The CRO for Point of Care and PMA Diagnostics.